Omada Health announced today that it has earned preferred status on the Evernorth Digital Health Formulary for its cardiometabolic digital chronic care programs: Diabetes, Hypertension and Prevention. As a preferred solution, participating employers and health plans have the ability to simplify their integration experience with Omada Health through Express Scripts, a pharmacy benefit manager that supports over 100 million members.
Evernorth added Omada Health to the Digital Health Formulary in December of 2019. During the last year, Omada’s programs have been evaluated through the Evernorth Digital Health Formulary process resulting in Omada’s programs gaining preferred status for their Diabetes, Hypertension and Prevention products. The preferred status expands Omada’s access to Evernorth members who are in need of cardiometabolic solutions while allowing individuals a holistic experience by including access to Evernorth’s care teams.
Chronic conditions remain the most difficult to manage and treat. 90% of the U.S. $3.8 trillion annual healthcare expenditures are for people with chronic and mental health conditions. To address that challenge, the healthcare sector has responded with new technologies and endless innovation that equates to a projected growth of $500 billion dollars. All this innovation, unfortunately, has made it difficult for partners and patients alike to identify the best solutions. Omada’s preferred status showcases the value of our virtual-first programs that are ingrained in meaningful relationships between healthcare professionals and patients, and are key to optimal chronic disease prevention and management.
Omada has more than 1,600 customers with 88% of their members satisfied with their programs and outcomes – and 94% of members achieving their desired health outcomes.
“Omada Health is unlike any other in the digital health landscape as our virtual-first programs leverage real humans, supported by technology to drive real healthcare outcomes,” said Wei-Li Shao, President of Omada Health. “The preferred status of our prevention, diabetes and hypertension programs from Evernorth, opens the doors for us to continue to deliver those clinically validated outcomes to millions more people. For our existing and future customers, this opportunity allows us to challenge and ultimately improve our care management for those with chronic conditions.”
“Evernorth’s preferred status recognition is a validating moment for Omada Health’s mission and direction,” said Omada CEO and Co-founder, Sean Duffy. “The rigorous evaluation process and Evernorth’s eagle-eyed attention to clinical validation showcases how Omada’s capabilities, rooted in virtual-first care, are a reliable solution to healthcare professionals and patients alike. We are fundamentally changing the approach to chronic disease management, and this news and our partnership with Evernorth takes us there even more quickly.”
If you’re interested in learning more about Omada and Evernorth’s partnership, please contact an Omada Benefits Advisor or your Express Scripts Account Executive.
About Omada Health
Omada Health combines the latest clinical protocols with breakthrough behavior science to make it possible for people with chronic conditions to achieve long term improvements in their health. Working with over 1,600 customers – including health plans, health systems, and Fortune 500 and small- and medium-sized employers across a variety of industries (food service, retail, manufacturing, etc.) – the company delivers personalized interventions for diabetes and diabetes prevention, hypertension, musculoskeletal issues and behavioral health. Omada Health’s digital care programs are clinically supported and evidence-based, and have had its results published in multiple peer-reviewed journals. Omada builds programs that employees don’t just try, but stick with – resulting in reduced healthcare costs that deliver long term changes in health behavior and increased ROI. To learn more, visit www.omadahealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005175/en/